Here, we found that three other agents employed in the Ma-Spore ALL 2003 regimen, methotrexate, vincristine, and L-asparaginase, are each individually able to overcome BIM deletion-associated GC resistance. The gene discussed is BCL2L11; the disease is acute lymphoblastic leukemia.